Research programme - malaria vaccines - Aduro/Protein Potential

Drug Profile

Research programme - malaria vaccines - Aduro/Protein Potential

Latest Information Update: 03 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Protein Potential
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 28 Oct 2015 Preclinical trials in Malaria in USA (unspecified route)
  • 19 Sep 2012 Aduro Biotech and Protein Potential receive a phase I SBIR grant from the National Institutes of Health for the development of Malaria vaccines
  • 19 Sep 2012 Early research in Malaria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top